Picture of Eisai Co logo

4523 Eisai Co Share Price

0.000.00%
jp flag iconLast trade - 00:00
HealthcareAdventurousLarge CapFalling Star

Momentum

Relative Strength (%)
1m-0.08%
3m-19.29%
6m-40.58%
1yr-41.73%
Volume Change (%)
10d/3m-38.19%
Price vs... (%)
52w High-47.55%
50d MA-5.36%
200d MA-23.73%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)34.76
PEG Ratio (f)2.28
EPS Growth (f)18.04%
Dividend Yield (f)2.83%
Valuation (ttm)IndustryMarket
Price to Book Value2.07
Price to Tang. Book3.31
Price to Free Cashflow47.44
Price to Sales2.26
EV to EBITDA15.48

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital6.17%
Return on Equity5.7%
Operating Margin8.51%

Financial Summary

Year End 31st MarUnit201920202021202220232024E2025ECAGR / Avg
Total Revenue¥m642,834695,621645,942756,226744,402735,541777,6144.41%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+37.04+92.15-68.86+11.2+15.58-23.49+18.04n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Eisai Co EPS forecast chart

Profile Summary

Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.

Directors

Last Annual
March 31st, 2023
Last Interim
December 31st, 2023
Incorporated
December 6th, 1941
Public Since
September 14th, 1961
No. of Shareholders
73,041
No. of Employees
11,076
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
jp flag iconTokyo Stock Exchange
Shares in Issue
287,036,241

4523 Share Price Performance

Upcoming Events for 4523

Full Year 2024 Eisai Co Ltd Earnings Release

Eisai Co Ltd Annual Shareholders Meeting

Q1 2025 Eisai Co Ltd Earnings Release

Similar to 4523

Picture of Astellas Pharma logo

Astellas Pharma

jp flag iconTokyo Stock Exchange

Picture of Astena Holdings Co logo

Astena Holdings Co

jp flag iconTokyo Stock Exchange

Picture of CanBas Co logo

CanBas Co

jp flag iconTokyo Stock Exchange

Picture of CellSeed logo

CellSeed

jp flag iconTokyo Stock Exchange

FAQ